BIORA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.705 USD | -0.98% |
|
-2.10% | -48.15% |
| May. 15 | Transcript : Biora Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024 | |
| May. 15 | Earnings Flash (BIOR) BIORA THERAPEUTICS Reports Q1 Revenue $542,000 | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 296.3 | 373.8 | 29.39 | 36.73 | 25.55 | - | - |
| Enterprise Value (EV) 1 | 363.1 | 411.8 | 29.39 | 36.73 | 25.55 | 25.55 | 25.55 |
| P/E ratio | -0.76 x | -0.81 x | -0.66 x | -0.17 x | -0.43 x | -0.57 x | -0.62 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 3.99 x | 6.17 x | 96.4 x | 9,183 x | 49 x | 10.2 x | 9.25 x |
| EV / Revenue | 3.99 x | 6.17 x | 96.4 x | 9,183 x | 49 x | 10.2 x | 9.25 x |
| EV / EBITDA | -1.59 x | -3.21 x | -0.48 x | -0.55 x | -0.36 x | -0.33 x | -0.29 x |
| EV / FCF | -1,735,677 x | -2,220,455 x | - | - | - | - | - |
| FCF Yield | -0% | -0% | - | - | - | - | - |
| Price to Book | -1.37 x | -2.37 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 2,232 | 7,154 | 8,927 | 27,209 | 35,884 | - | - |
| Reference price 2 | 132.8 | 52.25 | 3.292 | 1.350 | 0.7120 | 0.7120 | 0.7120 |
| Announcement Date | 3/18/21 | 3/28/22 | 3/30/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 144 | 74.31 | 60.61 | 0.305 | 0.004 | 0.521 | 2.502 | 2.762 |
| EBITDA 1 | - | -186.5 | -116.4 | -60.87 | -66.59 | -71.8 | -77.2 | -87.6 |
| EBIT 1 | - | -195.2 | -117.8 | -61.78 | -67.14 | -64.53 | -68.06 | -75.1 |
| Operating Margin | - | -262.66% | -194.42% | -20,256.07% | -1,678,575% | -12,386.28% | -2,719.78% | -2,718.46% |
| Earnings before Tax (EBT) 1 | - | -230.1 | -178.6 | -49.25 | -124.4 | -61.89 | -75.54 | -81.07 |
| Net income 1 | -148 | -192.8 | -247.4 | -38.16 | -124.1 | -61.94 | -75.54 | -81.07 |
| Net margin | -102.81% | -259.44% | -408.21% | -12,510.49% | -3,102,875% | -11,887.91% | -3,018.48% | -2,934.75% |
| EPS 2 | - | -175.2 | -64.25 | -5.000 | -7.870 | -1.640 | -1.240 | -1.145 |
| Free Cash Flow | - | -170.7 | -168.3 | - | - | - | - | - |
| FCF margin | - | -229.69% | -277.75% | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/19/20 | 3/18/21 | 3/28/22 | 3/30/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.66 | 1.375 | 0.104 | 0.08 | 0.014 | - | 0.002 | - | - | 0.542 | - | - | - |
| EBITDA 1 | - | -19.91 | -14.21 | -13.89 | -13.31 | - | -14.77 | -23.2 | -13.23 | -15.41 | -16.5 | -19.1 | -20.7 |
| EBIT 1 | -20.16 | -21.76 | -14.21 | -13.89 | -13.47 | - | - | -23.32 | -13.34 | - | -14 | -13.98 | -13.77 |
| Operating Margin | -263.17% | -1,582.69% | -13,663.46% | -17,358.75% | -96,207.14% | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -82.91 | -13.81 | -6.834 | -14.72 | -13.21 | - | -17.8 | -73.45 | -15.73 | -4.141 | -16.29 | -16.09 | -18.32 |
| Net income 1 | -92.87 | -13.81 | -5.513 | -5.114 | -13.72 | - | -17.81 | -73.45 | -15.41 | -4.189 | -16.29 | -16.09 | -18.32 |
| Net margin | -1,212.45% | -1,004.22% | -5,300.96% | -6,392.5% | -98,014.29% | - | -890,350% | - | - | -772.88% | - | - | - |
| EPS 2 | -14.00 | -2.000 | -0.7500 | -0.7500 | -1.640 | -1.590 | -1.470 | -4.890 | -0.6200 | -0.1400 | -0.4500 | -0.4200 | -0.4150 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/28/22 | 5/10/22 | 8/15/22 | 11/14/22 | 3/30/23 | 5/15/23 | 8/14/23 | 11/13/23 | 3/26/24 | 5/15/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | 66.8 | 38 | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.3583 x | -0.3264 x | - | - | - | - | - |
| Free Cash Flow | - | -171 | -168 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | -150% | -188% | - | - | - | - | - |
| Assets 1 | - | 128.3 | 131.6 | - | - | - | - | - |
| Book Value Per Share | - | -97.20 | -22.10 | - | - | - | - | - |
| Cash Flow per Share | - | -151.0 | -43.50 | - | - | - | - | - |
| Capex | - | 4.94 | 0.86 | - | - | - | - | - |
| Capex / Sales | - | 6.65% | 1.41% | - | - | - | - | - |
| Announcement Date | 3/19/20 | 3/18/21 | 3/28/22 | 3/30/23 | 3/26/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.712
USD
Average target price
10.3
USD
Spread / Average Target
+1,346.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -48.15% | 25.55M | |
| +9.43% | 114B | |
| +13.39% | 107B | |
| -10.34% | 22.22B | |
| -1.80% | 21.28B | |
| -4.64% | 18.8B | |
| -5.49% | 17.51B | |
| -39.93% | 17.17B | |
| +7.56% | 14.14B | |
| +34.78% | 12.2B |
- Stock Market
- Equities
- BIOR Stock
- Financials Biora Therapeutics, Inc.